Ozempic maker Novo Nordisk sets sights on hair-loss market

The condition is part of a list of areas, including addiction and menopause, where Novo sees potential overlap with either its core scientific expertise or the skills it's recently built in selling prescription drugs directly to consumers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A7nF6lZ
via IFTTT